Cardiovascular complications of HIV infection and treatment

Cardiovascular and Hematological Agents in Medicinal Chemistry

Volumn 11, Issue 1, 2013, Pages 58-66

  Garg, Himanshu ^a   Joshi, Anjali ^a   Mukherjee, Debabrata ^b  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b Paul L Foster School of Medicine   (United States)

Author keywords

Adverse events; Cardiovascular disease; Drug toxicity; Dyslipidemia; HAART; HIV; Infectious diseases; Mitochondria; Protease inhibitors; Reverse transcriptase inhibitors; Virus

Indexed keywords

ABACAVIR; AMPRENAVIR; ATAZANAVIR; CD4 ANTIGEN; DARUNAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; ETRAVIRINE; FOSAMPRENAVIR; INDINAVIR; LAMIVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NELFINAVIR; NEVIRAPINE; RALTEGRAVIR; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; THYMIDINE KINASE; THYMIDINE TRIPHOSPHATE; TIPRANAVIR; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; ZALCITABINE; ZIDOVUDINE;

CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CONGESTIVE HEART FAILURE; DILATATION; DRUG MECHANISM; DRUG MEGADOSE; HEART LEFT VENTRICLE FAILURE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPOSI SARCOMA; NONHUMAN; REVIEW;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CARDIOVASCULAR DISEASES; HIV INFECTIONS; HUMANS;

EID: 84873196601     PISSN: 18715257     EISSN: 18756182     Source Type: Journal    
DOI: 10.2174/1871525711311010010     Document Type: Review

References (86)

1. Aberg, J.A. Cardiovascular complications in HIV management: past, present, and future. J. Acquir. Immune Defic. Syndr., 2009, 50(1), 54-64.
2. Marin, B.; Thiebaut, R.; Bucher, H.C.; Rondeau, V.; Costagliola, D.; Dorrucci, M.; Hamouda, O.; Prins, M.; Walker, S.; Porter, K.; Sabin, C.; Chene, G. Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy. AIDS, 2009, 23(13), 1743-1753.
3. Palella, F.J., Jr.; Baker, R.K.; Moorman, A.C.; Chmiel, J.S.; Wood, K.C.; Brooks, J.T.; Holmberg, S.D. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J. Acquir. Immune Defic. Syndr., 2006, 43(1), 27-34.
4. Bedimo, R.J.; Westfall, A.O.; Drechsler, H.; Vidiella, G.; Tebas, P. Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era. Clin. Infect. Dis., 2011, 53(1), 84-91.
5. Sani, M.U. Myocardial disease in human immunodeficiency virus (HIV) infection: a review. Wien Klin Wochenschr., 2008, 120(3-4), 77-87.
6. Melzi, S.; Carenzi, L.; Cossu, M.V.; Passerini, S.; Capetti, A.; Rizzardini, G. Lipid Metabolism and Cardiovascular Risk in HIV-1 Infection and HAART: Present and Future Problems. Cholesterol., 2010, 2010, 271504.
7. Garg, H.; Viard, M.; Jacobs, A.; Blumenthal, R. Targeting HIV-1 gp41-induced fusion and pathogenesis for anti-viral therapy. Curr. Top. Med. Chem., 2011, 11(24), 2947-2958.
8. Barbaro, G.; Lipshultz, S.E. Pathogenesis of HIV-associated cardiomyopathy. Ann. N. Y. Acad. Sci., 2001, 946, 57-81.
9. Del Corno, M.; Liu, Q.H.; Schols, D.; de Clercq, E.; Gessani, S.; Freedman, B.D.; Collman, R.G. HIV-1 gp120 and chemokine activation of Pyk2 and mitogen-activated protein kinases in primary macrophages mediated by calcium-dependent, pertussis toxin-insensitive chemokine receptor signaling. Blood, 2001, 98(10), 2909-2916.
10. Kan, H.; Xie, Z.; Finkel, M.S. p38 MAP kinase-mediated negative inotropic effect of HIV gp120 on cardiac myocytes. Am. J. Physiol. Cell Physiol., 2004, 286(1), C1-7.
11. Kan, H.; Xie, Z.; Finkel, M.S. HIV gp120 enhances NO production by cardiac myocytes through p38 MAP kinase-mediated NFkappaB activation. Am. J. Physiol. Heart Circ. Physiol., 2000, 279(6), H3138-3143.
12. Zheng, M.; Zhang, S.J.; Zhu, W.Z.; Ziman, B.; Kobilka, B.K.; Xiao, R.P. beta 2-adrenergic receptor-induced p38 MAPK activation is mediated by protein kinase A rather than by Gi or gbeta gamma in adult mouse cardiomyocytes. J. Biol. Chem., 2000, 275(51), 40635-40640.
13. Bernardo, A.; Patrizio, M.; Levi, G.; Petrucci, T.C. Human immunodeficiency virus protein gp120 interferes with betaadrenergic receptor-mediated protein phosphorylation in cultured rat cortical astrocytes. Cell. Mol. Neurobiol., 1994, 14(2), 159-173.
14. Hellerstein, M.K.; Grunfeld, C.; Wu, K.; Christiansen, M.; Kaempfer, S.; Kletke, C.; Shackleton, C.H. Increased de novo hepatic lipogenesis in human immunodeficiency virus infection. J. Clin. Endocrinol. Metab., 1993, 76(3), 559-565.
15. Grossman, Z.; Meier-Schellersheim, M.; Paul, W.E.; Picker, L.J. Pathogenesis of HIV infection: what the virus spares is as important as what it destroys. Nat. Med., 2006, 12(3), 289-295.
16. Barbaro, G.; Di Lorenzo, G.; Soldini, M.; Giancaspro, G.; Grisorio, B.; Pellicelli, A.; Barbarini, G. Intensity of myocardial expression of inducible nitric oxide synthase influences the clinical course of human immunodeficiency virus-associated cardiomyopathy. Gruppo Italiano per lo Studio Cardiologico dei pazienti affetti da AIDS (GISCA). Circulation, 1999, 100(9), 933-939.
17. Otedo, A.E.; Oyoo, G.O.; Obondi, J.O.; Otieno, C.F. Vasculitis in HIV: report of eight cases. East Afr. Med. J., 2005, 82(12), 656-659.
18. Barbaro, G.; Di Lorenzo, G.; Grisorio, B.; Barbarini, G. Cardiac involvement in the acquired immunodeficiency syndrome: a multicenter clinical-pathological study. Gruppo Italiano per lo Studio Cardiologico dei pazienti affetti da AIDS Investigators. AIDS Res. Hum. Retroviruses, 1998, 14(12), 1071-1077.
19. Chi, D.; Henry, J.; Kelley, J.; Thorpe, R.; Smith, J.K.; Krishnaswamy, G. The effects of HIV infection on endothelial function. Endothelium, 2000, 7(4), 223-242.
20. Barbaro, G.; Barbarini, G.; Pellicelli, A.M. HIV-associated coronary arteritis in a patient with fatal myocardial infarction. N. Engl. J. Med., 2001, 344(23), 1799-1800.
21. Jerico, C.; Knobel, H.; Montero, M.; Sorli, M.L.; Guelar, A.; Gimeno, J.L.; Saballs, P.; Lopez-Colomes, J.L.; Pedro-Botet, J. Hypertension in HIV-infected patients: prevalence and related factors. Am. J. Hypertens., 2005, 18(11), 1396-1401.
22. Ho, D.D.; Pomerantz, R.J.; Kaplan, J.C. Pathogenesis of infection with human immunodeficiency virus. N. Engl. J. Med., 1987, 317(5), 278-286.
23. Baekken, M.; Os, I.; Sandvik, L.; Oektedalen, O. Hypertension in an urban HIV-positive population compared with the general population: influence of combination antiretroviral therapy. J. Hypertens., 2008, 26(11), 2126-2133.
24. Grandi, A.M.; Nicolini, E.; Giola, M.; Gianni, M.; Maresca, A.M.; Marchesi, C.; Guasti, L.; Balsamo, M.L.; Venco, A.; Grossi, P.A. Left ventricular remodelling in asymptomatic HIV infection on chronic HAART: comparison between hypertensive and normotensive subjects with and without HIV infection. J. Hum. Hypertens., 2011, [Epub ahead of print].
25. Mocroft, A.; Gatell, J.; Reiss, P.; Ledergerber, B.; Kirk, O.; Vella, S.; Blaxhult, A.; Phillips, A.N.; Lundgren, J. Causes of death in HIV infection: the key determinant to define the clinical response to anti-HIV therapy. AIDS, 2004, 18(17), 2333-2337.
26. Duong, M.; Dubois, C.; Buisson, M.; Eicher, J.C.; Grappin, M.; Chavanet, P.; Portier, H. Non-Hodgkin's lymphoma of the heart in patients infected with human immunodeficiency virus. Clin. Cardiol., 1997, 20(5), 497-502.
27. Hammer, S.M.; Eron, J.J. Jr.; Reiss, P.; Schooley, R.T.; Thompson, M.A.; Walmsley, S.; Cahn, P.; Fischl, M.A.; Gatell, J.M.; Hirsch, M.S.; Jacobsen, D.M.; Montaner, J.S.; Richman, D.D.; Yeni, P.G.; Volberding, P.A. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA, 2008, 300(5), 555-570.
28. Olivero, O.A. Mechanisms of genotoxicity of nucleoside reverse transcriptase inhibitors. Environ. Mol. Mutagen., 2007, 48(3-4), 215-223.
29. El Safadi, Y.; Vivet-Boudou, V.; Marquet, R. HIV-1 reverse transcriptase inhibitors. Appl. Microbiol. Biotechnol., 2007, 75(4), 723-737.
30. Feng, J.Y.; Johnson, A.A.; Johnson, K.A.; Anderson, K.S. Insights into the molecular mechanism of mitochondrial toxicity by AIDS drugs. J. Biol. Chem., 2001, 276(26), 23832-23837.
31. De Clercq, E. Non-nucleoside reverse transcriptase inhibitors (NNRTIs): past, present, and future. Chem Biodivers., 2004, 1(1), 44-64.
32. Huang, P.; Farquhar, D.; Plunkett, W. Selective action of 2',3'-didehydro-2',3'-dideoxythymidine triphosphate on human immunodeficiency virus reverse transcriptase and human DNA polymerases. J. Biol. Chem., 1992, 267(4), 2817-2822.
33. Huang, P.; Farquhar, D.; Plunkett, W. Selective action of 3'-azido-3'-deoxythymidine 5'-triphosphate on viral reverse transcriptases and human DNA polymerases. J. Biol. Chem., 1990, 265(20), 11914-11918.
34. Lim, S.E.; Copeland, W.C. Differential incorporation and removal of antiviral deoxynucleotides by human DNA polymerase gamma. J. Biol. Chem., 2001, 276(26), 23616-23623.
35. Lewis, W.; Day, B.J.; Copeland, W.C. Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective. Nat Rev. Drug Discov., 2003, 2(10), 812-822.
36. Lund, K.C.; Wallace, K.B. Direct effects of nucleoside reverse transcriptase inhibitors on rat cardiac mitochondrial bioenergetics. Mitochondrion., 2004, 4(2-3), 193-202.
37. Venhoff, N.; Setzer, B.; Melkaoui, K.; Walker, U.A. Mitochondrial toxicity of tenofovir, emtricitabine and abacavir alone and in combination with additional nucleoside reverse transcriptase inhibitors. Antivir. Ther., 2007, 12(7), 1075-1085.
38. Lewis, W.; Gonzalez, B.; Chomyn, A.; Papoian, T. Zidovudine induces molecular, biochemical, and ultrastructural changes in rat skeletal muscle mitochondria. J. Clin. Invest., 1992, 89(4), 1354-1360.
39. Benbrik, E.; Chariot, P.; Bonavaud, S.; Ammi-Said, M.; Frisdal, E.; Rey, C.; Gherardi, R.; Barlovatz-Meimon, G. Cellular and mitochondrial toxicity of zidovudine (AZT), didanosine (ddI) and zalcitabine (ddC) on cultured human muscle cells. J. Neurol. Sci., 1997, 149(1), 19-25.
40. Dube, M.P.; Stein, J.H.; Aberg, J.A.; Fichtenbaum, C.J.; Gerber, J.G.; Tashima, K.T.; Henry, W.K.; Currier, J.S.; Sprecher, D.; Glesby, M.J. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin. Infect. Dis., 2003, 37(5), 613-627.
41. Englund, J.A.; Raskino, C.; Vavro, C.; Palumbo, P.; Ross, L.L.; McKinney, R.; Nikolic-Djokic, D.; Colgrove, R.C.; Baker, C.J. Mutations linked to drug resistance, human immunodeficiency virus type 1 biologic phenotype and their association with disease progression in children receiving nucleoside reverse transcriptase inhibitors. Pediatr. Infect. Dis. J., 2004, 23(1), 15-22.
42. Hoggard, P.G.; Back, D.J. Intracellular pharmacology of nucleoside analogues and protease inhibitors: role of transporter molecules. Curr. Opin. Infect. Dis., 2002, 15(1), 3-8.
43. Dolce, V.; Fiermonte, G.; Runswick, M.J.; Palmieri, F.; Walker, J.E. The human mitochondrial deoxynucleotide carrier and its role in the toxicity of nucleoside antivirals. Proc. Natl. Acad. Sci. USA, 2001, 98(5), 2284-2288.
44. Cote, H.C. Possible ways nucleoside analogues can affect mitochondrial DNA content and gene expression during HIV therapy. Antivir. Ther., 2005, 10(Suppl. 2), M3-11.
45. Kohler, J.J.; Hosseini, S.H.; Cucoranu, I.; Hoying-Brandt, A.; Green, E.; Johnson, D.; Wittich, B.; Srivastava, J.; Ivey, K.; Fields, E.; Russ, R.; Raper, C.M.; Santoianni, R.; Lewis, W. Murine cardiac mtDNA: effects of transgenic manipulation of nucleoside phosphorylation. Lab. Invest., 2009, 89(2), 122-130.
46. Kohler, J.J.; Hosseini, S.H.; Green, E.; Hoying-Brandt, A.; Cucoranu, I.; Haase, C.P.; Russ, R.; Srivastava, J.; Ivey, K.; Ludaway, T.; Kapoor, V.; Abuin, A.; Shapoval, A.; Santoianni, R.; Saada, A.; Elpeleg, O.; Lewis, W. Cardiac-targeted transgenic mutant mitochondrial enzymes: mtDNA defects, antiretroviral toxicity and cardiomyopathy. Cardiovasc. Toxicol., 2008, 8(2), 57-69.
47. Hosseini, S.H.; Kohler, J.J.; Haase, C.P.; Tioleco, N.; Stuart, T.; Keebaugh, E.; Ludaway, T.; Russ, R.; Green, E.; Long, R.; Wang, L.; Eriksson, S.; Lewis, W. Targeted transgenic overexpression of mitochondrial thymidine kinase (TK2) alters mitochondrial DNA (mtDNA) and mitochondrial polypeptide abundance: transgenic TK2, mtDNA, and antiretrovirals. Am. J. Pathol., 2007, 170(3), 865-874.
48. Domingo, P.; Cabeza, M.C.; Pruvost, A.; Torres, F.; Salazar, J.; del Mar Gutierrez, M.; Mateo, M.G.; Fontanet, A.; Fernandez, I.; Domingo, J.C.; Villarroya, F.; Vidal, F.; Baiget, M. Association of thymidylate synthase gene polymorphisms with stavudine triphosphate intracellular levels and lipodystrophy. Antimicrob. Agents Chemother., 2011, 55(4), 1428-1435.
49. McKee, E.E.; Bentley, A.T.; Hatch, M.; Gingerich, J.; Susan-Resiga, D. Phosphorylation of thymidine and AZT in heart mitochondria: elucidation of a novel mechanism of AZT cardiotoxicity. Cardiovasc Toxicol., 2004, 4(2), 155-167.
50. Wang, L.; Sun, R.; Eriksson, S. The kinetic effects on thymidine kinase 2 by enzyme-bound dTTP may explain the mitochondrial side effects of antiviral thymidine analogs. Antimicrob. Agents Chemother., 2011, 55(6), 2552-2558.
51. Groschel, B.; Kaufmann, A.; Hover, G.; Cinatl, J.; Doerr, H.W.; Noordhuis, P.; Loves, W.J.; Peters, G.J.; Cinatl, J., Jr. 3'-Azido-2',3'-dideoxythymidine induced deficiency of thymidine kinases 1, 2 and deoxycytidine kinase in H9 T-lymphoid cells. Biochem. Pharmacol., 2002, 64(2), 239-246.
52. Mansoor, A.; Golub, E.T.; Dehovitz, J.; Anastos, K.; Kaplan, R.C.; Lazar, J.M. The association of HIV infection with left ventricular mass/hypertrophy. AIDS Res. Hum. Retroviruses, 2009, 25(5), 475-481.
53. Gao, R.Y.; Mukhopadhyay, P.; Mohanraj, R.; Wang, H.; Horvath, B.; Yin, S.; Pacher, P. Resveratrol attenuates azidothymidineinduced cardiotoxicity by decreasing mitochondrial reactive oxygen species generation in human cardiomyocytes. Mol. Med. Report., 2011, 4(1), 151-155.
54. de la Asuncion, J.G.; Del Olmo, M.L.; Gomez-Cambronero, L.G.; Sastre, J.; Pallardo, F.V.; Vina, J. AZT induces oxidative damage to cardiac mitochondria: protective effect of vitamins C and E. Life Sci., 2004, 76(1), 47-56.
55. Carr, A. Cardiovascular risk factors in HIV-infected patients. J. Acquir. Immune Defic. Syndr., 2003, 34(Suppl. 1), S73-78.
56. Carr, A.; Samaras, K.; Chisholm, D.J.; Cooper, D.A. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet, 1998, 351(9119), 1881-1883.
57. Carr, A.; Samaras, K.; Chisholm, D.J.; Cooper, D.A. Abnormal fat distribution and use of protease inhibitors. Lancet, 1998, 351(9117), 1736.
58. Carr, A.; Samaras, K.; Thorisdottir, A.; Kaufmann, G.R.; Chisholm, D.J.; Cooper, D.A. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet, 1999, 353(9170), 2093-2099.
59. Periard, D.; Telenti, A.; Sudre, P.; Cheseaux, J.J.; Halfon, P.; Reymond, M.J.; Marcovina, S.M.; Glauser, M.P.; Nicod, P.; Darioli, R.; Mooser, V. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation, 1999, 100(7), 700-705.
60. Thomas, C.M.; Smart, E.J. How HIV protease inhibitors promote atherosclerotic lesion formation. Curr. Opin. Lipidol., 2007, 18(5), 561-565.
61. Hui, D.Y. Effects of HIV protease inhibitor therapy on lipid metabolism. Prog. Lipid Res., 2003, 42(2), 81-92.
62. Parker, R.A.; Flint, O.P.; Mulvey, R.; Elosua, C.; Wang, F.; Fenderson, W.; Wang, S.; Yang, W.P.; Noor, M.A. Endoplasmic reticulum stress links dyslipidemia to inhibition of proteasome activity and glucose transport by HIV protease inhibitors. Mol. Pharmacol., 2005, 67(6), 1909-1919.
63. De Barros, S.; Zakaroff-Girard, A.; Lafontan, M.; Galitzky, J.; Bourlier, V. Inhibition of human preadipocyte proteasomal activity by HIV protease inhibitors or specific inhibitor lactacystin leads to a defect in adipogenesis, which involves matrix metalloproteinase-9. J. Pharmacol. Exp. Ther., 2007, 320(1), 291-299.
64. Pajonk, F.; Himmelsbach, J.; Riess, K.; Sommer, A.; McBride, W.H. The human immunodeficiency virus (HIV)-1 protease inhibitor saquinavir inhibits proteasome function and causes apoptosis and radiosensitization in non-HIV-associated human cancer cells. Cancer Res., 2002, 62(18), 5230-5235.
65. Schmidtke, G.; Holzhutter, H.G.; Bogyo, M.; Kairies, N.; Groll, M.; de Giuli, R.; Emch, S.; Groettrup, M. How an inhibitor of the HIV-I protease modulates proteasome activity. J. Biol. Chem., 1999, 274(50), 35734-35740.
66. Murata, H.; Hruz, P.W.; Mueckler, M. Investigating the cellular targets of HIV protease inhibitors: implications for metabolic disorders and improvements in drug therapy. Curr. Drug Targets Infect. Disord., 2002, 2(1), 1-8.
67. Coffinier, C.; Hudon, S.E.; Farber, E.A.; Chang, S.Y.; Hrycyna, C.A.; Young, S.G.; Fong, L.G. HIV protease inhibitors block the zinc metalloproteinase ZMPSTE24 and lead to an accumulation of prelamin A in cells. Proc. Natl. Acad. Sci. USA, 2007, 104(33), 13432-13437.
68. Goulbourne, C.N.; Vaux, D.J. HIV protease inhibitors inhibit FACE1/ZMPSTE24: a mechanism for acquired lipodystrophy in patients on highly active antiretroviral therapy? Biochem. Soc. Trans., 2010, 38(Pt. 1), 292-296.
69. Liang, J.S.; Distler, O.; Cooper, D.A.; Jamil, H.; Deckelbaum, R.J.; Ginsberg, H.N.; Sturley, S.L. HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia. Nat. Med., 2001, 7(12), 1327-1331.
70. Dressman, J.; Kincer, J.; Matveev, S.V.; Guo, L.; Greenberg, R.N.; Guerin, T.; Meade, D.; Li, X.A.; Zhu, W.; Uittenbogaard, A.; Wilson, M.E.; Smart, E.J. HIV protease inhibitors promote atherosclerotic lesion formation independent of dyslipidemia by increasing CD36-dependent cholesteryl ester accumulation in macrophages. J. Clin. Invest., 2003, 111(3), 389-397.
71. Cianflone, K.; Zakarian, R.; Couillard, C.; Delplanque, B.; Despres, J.P.; Sniderman, A. Fasting acylation-stimulating protein is predictive of postprandial triglyceride clearance. J. Lipid Res., 2004, 45(1), 124-131.
72. Jiang, B.; Hebert, V.Y.; Zavecz, J.H.; Dugas, T.R. Antiretrovirals induce direct endothelial dysfunction in vivo. J. Acquir. Immune Defic. Syndr., 2006, 42(4), 391-395.
73. Chai, H.; Yang, H.; Yan, S.; Li, M.; Lin, P.H.; Lumsden, A.B.; Yao, Q.; Chen, C. Effects of 5 HIV protease inhibitors on vasomotor function and superoxide anion production in porcine coronary arteries. J. Acquir. Immune Defic. Syndr., 2005, 40(1), 12-19.
74. Samaras, K.; Wand, H.; Law, M.; Emery, S.; Cooper, D.; Carr, A. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia. Diabetes Care, 2007, 30(1), 113-119.
75. Worm, S.W.; Friis-Moller, N.; Bruyand, M.; D'Arminio Monforte, A.; Rickenbach, M.; Reiss, P.; El-Sadr, W.; Phillips, A.; Lundgren, J.; Sabin, C. High prevalence of the metabolic syndrome in HIVinfected patients: impact of different definitions of the metabolic syndrome. AIDS, 2010, 24(3), 427-435.
76. Koster, J.C.; Remedi, M.S.; Qiu, H.; Nichols, C.G.; Hruz, P.W. HIV protease inhibitors acutely impair glucose-stimulated insulin release. Diabetes, 2003, 52(7), 1695-1700.
77. Vyas, A.K.; Koster, J.C.; Tzekov, A.; Hruz, P.W. Effects of the HIV protease inhibitor ritonavir on GLUT4 knock-out mice. J. Biol. Chem., 2010, 285(47), 36395-36400.
78. Blanchard, D.G.; Hagenhoff, C.; Chow, L.C.; McCann, H.A.; Dittrich, H.C. Reversibility of cardiac abnormalities in human immunodeficiency virus (HIV)-infected individuals: a serial echocardiographic study. J. Am. Coll. Cardiol., 1991, 17(6), 1270-1276.
79. Barbaro, G.; Barbarini, G.; Di Lorenzo, G. Early impairment of systolic and diastolic function in asymptomatic HIV-positive patients: a multicenter echocardiographic and echo-Doppler study. The Gruppo Italiano Per lo Studio Cardiologico dei Pazienti Affetti da AIDS. AIDS Res. Hum. Retroviruses, 1996, 12(16), 1559-1563.
80. Barbaro, G.; Di Lorenzo, G.; Grisorio, B.; Barbarini, G. Incidence of dilated cardiomyopathy and detection of HIV in myocardial cells of HIV-positive patients. Gruppo Italiano per lo Studio Cardiologico dei Pazienti Affetti da AIDS. N. Engl. J. Med., 1998, 339(16), 1093-1099.
81. Nahass, R.G.; Weinstein, M.P.; Bartels, J.; Gocke, D.J. Infective endocarditis in intravenous drug users: a comparison of human immunodeficiency virus type 1-negative and-positive patients. J. Infect. Dis., 1990, 162(4), 967-970.
82. d'Amati, G.; di Gioia, C.R.; Gallo, P. Pathological findings of HIVassociated cardiovascular disease. Ann. N. Y. Acad. Sci., 2001, 946, 23-45.
83. Petrosillo, N.; Pugliese, G.; Girardi, E.; Pallavicini, F.; Carosi, G.; Moro, M.L.; Ippolito, G. Nosocomial infections in HIV infected patients. Gruppo HIV e Infezioni Ospedaliere. AIDS, 1999, 13(5), 599-605.
84. Umana, E.; Panayiotou, H.; Ramsey, K.A.; Bikkina, M.; Massey, C.V.; Alpert, M.A. Left ventricular mass and systolic function in human immunodeficiency virus-infected patients after weight loss. Am. J. Cardiol., 2000, 86(9), 1040-1043, A1011.
85. Martinez-Garcia, T.; Sobrino, J.M.; Pujol, E.; Galvez, J.; Benitez, E.; Giron-Gonzalez, J.A. Ventricular mass and diastolic function in patients infected by the human immunodeficiency virus. Heart, 2000, 84(6), 620-624.
86. Cardoso, J.S.; Moura, B.; Martins, L.; Mota-Miranda, A.; Rocha Goncalves, F.; Lecour, H. Left ventricular dysfunction in human immunodeficiency virus (HIV)-infected patients. Int. J. Cardiol., 1998, 63(1), 37-45.